CONFERENCE DAY TWO
7:15 am Check-in & Morning Coffee
8:15 am Chair’s Opening Remarks
Advancing Bifunctionals Towards the First Approval with Clinical Data from Leaders in Clinic
8:30 am Driving Progress for a Differentiated Oral Oncology Degrader
Synopsis
- Identification of a potent, selective, and orally bioavailable degrader
- World-class degrader platform utilized for effective modeling
- Effective progression through dose finding escalation cohorts
9:00 am Clinical Activity of NX-5948 in CLL & NHL: A First-in-Class BTK Degrader
Synopsis
- Emerging clinical data support utility of novel MOA against validated target
- Activity demonstrated in the CNS and in patients harboring BTKi resistance mutations
9:30 am Enabling Insights into Molecular Glue MoA Toward Design of Potent & Selective CK1a Degraders
Synopsis
- Understanding neosubstrate selectivity through degradation and ternary complex profiling of CRBN molecular glues
- Development of a potent CK1a-selective degrader guided by cellular degradation and ternary complex studies
- Correlating specific target degradation with cellular outcomes
10:00 am Teaching CRBN New Tricks
Synopsis
- Monte Rosa’s QuEEN™ discovery engine is unlocking new target space amenable to the rational design of CRBN-based molecular glue degraders
- AI-driven prediction and structural validation of multiple novel binding modes demonstrates the extent to which CRBN can be reprogrammed as a an E3 ligase
- Specific examples of new targets with novel binding modes will be showcased during the presentation
10:30 am Morning Break & Networking
Novel Target & Pathway Identification & Selection to Unearth
New Molecular Glues
Download the Full Event Guide for full details
11:30am: Novel Molecular Glue Targets
Gregory Michaud, Director, Novartis
12:00pm: First-in-Class Molecular Glue Degrader of an RNA-Binding Protein to Treat BRAF-Mutant Tumor
Yong Cang, Chief Scientific Officer & Co-Founder, Degron Therapeutics
12:00pm: Presentation Brought to You by WuXi Apptec
Talk details TBC
12:50pm: Networking Lunch Break
Unravelling MOA & Optimizing Binding of Selective Degraders
Download the Full Event Guide for full details
2:00pm: Discovery of Novel Monovalent Degraders of SMARCA2/4
Joachim Rudolph, Senior Fellow, Genentech
2:30pm: Degrading Hard to Drug Disease Causing Extracellular Proteins
Shyra Gardai, Chief Scientific Officer, EpiBiologics
3:00pm: Afternoon Networking Break
CLOSING KEYNOTE PLENARY SESSION
Preparing for the Future: Accelerating Strategy, Partnering & Investment for TPD & Beyond
3:15 pm Introduction: A Review of the Current Trends in Platform Deals
Synopsis
10-minute high level overview of the past and recent deals with platforms in TPD & Induced Proximity
3:25 pm Panel Discussion: Lessons Learned from a Major Strategic Partnership Deal for a Platform
Synopsis
- Spotlighting some of the challenges and pitfalls when establishing a partnership
- Exploring the nuances of striking a deal for a discovery platform
- Zoning in on the opportunities created from a joint venture
- Considering how biotech can get the most out of an investment
4:00 pm Introduction: A Review of the Current Trends in Asset Deals
Synopsis
10-minute high level overview of the past and recent deals for early stage and later stage assets in TPD & Induced Proximity, for PROTACs, Molecular Glues, and beyond
4:10 pm Panel Discussion: Lessons Learned from a Major Strategic Partnership Deal for an Asset
Synopsis
- Spotlighting some of the challenges and pitfalls when establishing a partnership
- Exploring the nuances of striking a deal for a discovery platform
- Zoning in on the opportunities created from a joint venture
- Considering how biotech can get the most out of an investment
4:45 pm Solving Big Problems with Small Molecule Degraders
Synopsis
- To realize on the promise of this disease-agnostic technology, Kymera has taken a unique approach to target selection, where we focus on targets that are either undrugged or inadequately drugged within key signaling pathways with clear clinical validation and validation through human genetics/causal biology, and where TPD is the best or the only solution
- Our comprehensive drug discovery engine utilizes computational tools, fit-for-purpose technologies, and quantitative translational models to design potent and selective degraders and drive consistent fidelity of translation of safety, PK/PD, and early efficacy from preclinical models to patients
- Preclinical and early clinical findings across our immunology and oncology pipeline support a clear degrader advantage and our differentiated strategies to advance a new generation of medicines